Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258872 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL2347706 | 0.83 | GSK3B (0.36) | CYP1A2CYP3A4CYP2C19KMT2AALDH1A1 | |
| SCHEMBL12245352 | 0.81 | AKR1B1 (0.53) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL12245353 | 0.81 | AKR1B1 (0.44) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL2688006 | 0.80 | ALDH1A1 (0.39) | KDM4EMAPTGAAMEN1KMT2A | |
| SCHEMBL31514229 | 0.79 | GAA (0.40) | KDM4EMAPTGAAMEN1KMT2A | |
| SCHEMBL30755273 | 0.77 | KDM4E (0.50) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL1003898 | 0.77 | AKR1B1 (0.52) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL27373218 | 0.77 | KDM4E (0.50) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL12952514 | 0.77 | CYP1A2 (0.45) | CYP1A2CYP3A4CYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068452-A1 | GUANFACINE DERIVATIVES AND THEIR USE IN TREATING CANCER | NEGIO THERAPEUTICS (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107820494-B | Nuclear receptor modulators | 艾伯维公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2451767-B1 | METHOD FOR PRODUCING (2,4-DIMETHYLBIPHENYL-3-YL) ACETIC ACIDS, ESTERS THEREOF AND INTERCONNECTIONS | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-2451767-B1 | METHOD FOR PRODUCING (2,4-DIMETHYLBIPHENYL-3-YL) ACETIC ACIDS, ESTERS THEREOF AND INTERCONNECTIONS | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| CN-102471215-A | Process for preparing (2, 4-dimethylbiphenyl-3-yl) acetic acid, esters thereof and intermediate compounds | BAYER CROPSCIENCE AG | 2012-05-23 | — | — | CN | disclosed |
| EP-2451767-A2 | METHOD FOR PRODUCING (2,4-DIMETHYLBIPHENYL-3-YL)ACETIC ACIDS, THE ESTERS THEREOF AND INTERMEDIATE COMPOUNDS | Bayer CropScience AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011003530-A2 | METHOD FOR PRODUCING (2,4-DIMETHYLBIPHENYL-3-YL)ACETIC ACIDS, THE ESTERS THEREOF AND INTERMEDIATE COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | CYP1A2 255/4885CYP3A4 520/4885CYP2C19 502/4885 |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | AGXT, PTPRG, WIZ | CYP1A2 932/4885CYP3A4 1109/4885CYP2C19 1426/4885 |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | DDC, DDT, PAH | CYP1A2 195/4885CYP3A4 151/4885CYP2C19 108/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CYP1A2 284/4885CYP3A4 275/4885CYP2C19 325/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CYP1A2 284/4885CYP3A4 275/4885CYP2C19 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.